CEO Roundtable Panelist
Thomas Meier
CEO, Bachem Holding AG
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Thomas Meier joined Bachem AG in 1993 as Team Head, Active Pharmaceutical Ingredients. From 2001 to 2004, he headed up peptide manufacturing at Peninsula Laboratories, Inc. in San Carlos, California. Upon his return to Switzerland, he was in charge of solid-phase peptide manufacturing for Bachem AG in Bubendorf. He assumed overall responsibility for production at the Bubendorf site in 2013, and was appointed COO Europe in August 2017, with responsibility for all production sites in Switzerland, Germany, and the UK. He was appointed COO of the Bachem Group and member of the Corporate Executive Committee in 2019. Since January 1, 2020 Thomas Meier is CEO of the Bachem Group and Chairman of the Corporate Executive Committee.